Suppr超能文献

再生医学在普通外科中的应用。

Regenerative medicine as applied to general surgery.

机构信息

Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA.

出版信息

Ann Surg. 2012 May;255(5):867-80. doi: 10.1097/SLA.0b013e318243a4db.

Abstract

The present review illustrates the state of the art of regenerative medicine (RM) as applied to surgical diseases and demonstrates that this field has the potential to address some of the unmet needs in surgery. RM is a multidisciplinary field whose purpose is to regenerate in vivo or ex vivo human cells, tissues, or organs to restore or establish normal function through exploitation of the potential to regenerate, which is intrinsic to human cells, tissues, and organs. RM uses cells and/or specially designed biomaterials to reach its goals and RM-based therapies are already in use in several clinical trials in most fields of surgery. The main challenges for investigators are threefold: Creation of an appropriate microenvironment ex vivo that is able to sustain cell physiology and function in order to generate the desired cells or body parts; identification and appropriate manipulation of cells that have the potential to generate parenchymal, stromal and vascular components on demand, both in vivo and ex vivo; and production of smart materials that are able to drive cell fate.

摘要

本文综述了再生医学在外科疾病中的应用现状,证明了该领域有潜力解决外科领域的一些未满足的需求。再生医学是一个多学科领域,其目的是通过利用人类细胞、组织和器官固有的再生潜力,在体内或体外再生人类细胞、组织或器官,以恢复或建立正常功能。再生医学使用细胞和/或专门设计的生物材料来实现其目标,基于再生医学的疗法已经在大多数外科领域的几个临床试验中使用。研究人员面临的主要挑战有三方面:体外创造一个合适的微环境,使其能够维持细胞的生理和功能,以生成所需的细胞或身体部位;鉴定和适当操作具有按需在体内和体外生成实质、基质和血管成分潜力的细胞;以及生产能够驱动细胞命运的智能材料。

相似文献

1
Regenerative medicine as applied to general surgery.
Ann Surg. 2012 May;255(5):867-80. doi: 10.1097/SLA.0b013e318243a4db.
2
Extravasation of chemotherapy: an alternative clinical application of integra in hand and upper extremity surgery.
J Hand Surg Am. 2012 Aug;37(8):1749-50; author reply 1750. doi: 10.1016/j.jhsa.2012.05.041.
4
[The role of Integra dermal regeneration matrix in skin replacement on the upper extremity].
Orv Hetil. 2012 Aug 26;153(34):1351-5. doi: 10.1556/OH.2012.29438.
5
An overview of the therapeutic potential of regenerative medicine in cutaneous wound healing.
Int Wound J. 2017 Jun;14(3):450-459. doi: 10.1111/iwj.12735. Epub 2017 Mar 6.
6
Chondroitin sulfate: From bioactive molecule to versatile drug delivery system for advancing regenerative medicine.
Int J Biol Macromol. 2025 Jun;311(Pt 2):143746. doi: 10.1016/j.ijbiomac.2025.143746. Epub 2025 May 2.
7
Advent and maturation of regenerative medicine.
Curr Stem Cell Res Ther. 2012 Nov;7(6):430-45. doi: 10.2174/157488812804484657.
8
Silk fibroin/chondroitin sulfate/hyaluronic acid ternary scaffolds for dermal tissue reconstruction.
Acta Biomater. 2013 Jun;9(6):6771-82. doi: 10.1016/j.actbio.2013.02.016. Epub 2013 Feb 16.
9
The use of Integra in hand and upper extremity surgery.
J Hand Surg Am. 2012 Mar;37(3):583-6. doi: 10.1016/j.jhsa.2011.11.007. Epub 2011 Dec 29.
10
Apligraf treatment of venous ulcers and other chronic wounds.
J Dermatol. 1998 Dec;25(12):812-7. doi: 10.1111/j.1346-8138.1998.tb02510.x.

引用本文的文献

1
Mapping the blueprint of artificial blood vessels research: a bibliometric analysis.
Int J Surg. 2025 Jan 1;111(1):1014-1031. doi: 10.1097/JS9.0000000000001877.
3
Insights into optimizing exosome therapies for acute skin wound healing and other tissue repair.
Front Med. 2024 Apr;18(2):258-284. doi: 10.1007/s11684-023-1031-9. Epub 2024 Jan 13.
5
Therapeutic Benefits of Stem Cells and Exosomes for Sulfur-Mustard-Induced Tissue Damage.
Int J Mol Sci. 2023 Jun 9;24(12):9947. doi: 10.3390/ijms24129947.
6
Editorial: Scaffold Technology, Tissue and Organ Engineering: New Horizons in Surgery.
Front Surg. 2022 May 18;9:914080. doi: 10.3389/fsurg.2022.914080. eCollection 2022.
7
Nanofat: A therapeutic paradigm in regenerative medicine.
World J Stem Cells. 2021 Nov 26;13(11):1733-1746. doi: 10.4252/wjsc.v13.i11.1733.
9
A novel protocol for isolation and culture of multipotent progenitor cells from human urine.
J Orthop Translat. 2019 Mar 16;19:12-17. doi: 10.1016/j.jot.2019.02.005. eCollection 2019 Oct.
10
Urine-derived cells for human cell therapy.
Stem Cell Res Ther. 2018 Jul 11;9(1):189. doi: 10.1186/s13287-018-0932-z.

本文引用的文献

1
Tissue engineering in urethral reconstruction--an update.
Asian J Androl. 2013 Jan;15(1):89-92. doi: 10.1038/aja.2012.91. Epub 2012 Oct 8.
2
A combined cell therapy and in-situ tissue-engineering approach for myocardial repair.
Biomaterials. 2011 Oct;32(30):7514-23. doi: 10.1016/j.biomaterials.2011.06.049. Epub 2011 Jul 23.
3
Regenerative medicine and organ transplantation: past, present, and future.
Transplantation. 2011 Jun 27;91(12):1310-7. doi: 10.1097/TP.0b013e318219ebb5.
4
Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds.
Annu Rev Biomed Eng. 2011 Aug 15;13:27-53. doi: 10.1146/annurev-bioeng-071910-124743.
5
Tissue-engineered autologous urethras for patients who need reconstruction: an observational study.
Lancet. 2011 Apr 2;377(9772):1175-82. doi: 10.1016/S0140-6736(10)62354-9.
6
A whole-organ regenerative medicine approach for liver replacement.
Tissue Eng Part C Methods. 2011 Jun;17(6):677-86. doi: 10.1089/ten.TEC.2010.0698. Epub 2011 Apr 20.
7
Readily available tissue-engineered vascular grafts.
Sci Transl Med. 2011 Feb 2;3(68):68ra9. doi: 10.1126/scitranslmed.3001426.
8
The use of whole organ decellularization for the generation of a vascularized liver organoid.
Hepatology. 2011 Feb;53(2):604-17. doi: 10.1002/hep.24067. Epub 2011 Jan 10.
9
Tissue engineering in urethral reconstruction.
F1000 Med Rep. 2010 Sep 8;2:65. doi: 10.3410/M2-65.
10
In vivo performance of a phospholipid-coated bioerodable elastomeric graft for small-diameter vascular applications.
J Biomed Mater Res A. 2011 Feb;96(2):436-48. doi: 10.1002/jbm.a.32997. Epub 2010 Dec 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验